CN110652510A - Application of Zhongwuning in preparing medicine for preventing and treating renal fibrosis - Google Patents
Application of Zhongwuning in preparing medicine for preventing and treating renal fibrosis Download PDFInfo
- Publication number
- CN110652510A CN110652510A CN201910582562.4A CN201910582562A CN110652510A CN 110652510 A CN110652510 A CN 110652510A CN 201910582562 A CN201910582562 A CN 201910582562A CN 110652510 A CN110652510 A CN 110652510A
- Authority
- CN
- China
- Prior art keywords
- fibrosis
- renal
- group
- kidney
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine for preventing and treating nephritis and renal fibrosis. The medicine is the Chinese wuning or acceptable salt, ester or solvate thereof. The medicine is taken as an effective component, and can be prepared into a preparation with corresponding functions together with acceptable auxiliary materials or auxiliary components in the medicine. Research shows that the Chinese medicine Wuning has obvious effect of preventing and/or treating nephritis and kidney fibrosis.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to application of Zhongwuning in preparation of medicines and health-care products for treating renal fibrosis.
Background
Renal fibrosis is one of the pathological features of chronic renal failure, and is the ultimate destination of various chronic and progressive renal diseases, and the degree of the renal fibrosis determines the prognosis of the renal diseases, and is a common pathway for the development of various renal diseases to end-stage renal diseases (namely renal insufficiency). How to intervene in the development of renal interstitial fibrosis by using medicines is the key point for preventing and treating chronic renal failure. It is presently believed that the pathological changes in end-stage renal disease are irreversible and, therefore, it is critical to control the development of renal fibrosis. Modern medical research shows that: the pathogenesis of the renal fibrosis is complex, multiple factors are involved, different stages of the renal fibrosis generate imbalance of factors for promoting fibrosis and resisting fibrosis, imbalance of myofibroblast generation and apoptosis and imbalance of extracellular matrix (ECM) generation and degradation under the joint participation and regulation of a plurality of related cells, factors and active substances, so that inflammatory cell infiltration, myofibroblast activation, epithelial cell to mesenchymal cell transdifferentiation (EMT), ECM remodeling and excessive accumulation and renal intrinsic cell apoptosis sequentially occur.
The current clinical treatments for renal fibrosis mainly include: the treatment of primary diseases (such as obstructive nephropathy and the like), the elimination and intervention of related risk factors (such as infection, medicaments and the like) and the treatment aiming at pathogenesis (such as non-steroidal anti-inflammatory drugs and antihypertensive drugs). Although the above treatment method can play a certain role in treating kidney fibrosis, the development of chronic kidney disease to chronic renal insufficiency cannot be completely prevented, so that the search for a drug which can resist nephritis and kidney fibrosis and treat kidney fibrosis is necessary.
At present, no document or patent indicates that the Chinese medicine Wuning has the effect of resisting renal fibrosis, and a mode of tracking the activity of resisting renal fibrosis is adopted to separate and discover the Chinese medicine Wuning (mesaconine; Cas No. 6792-09-2; molecular formula C: C) from monkshood and aconite24H39NO9) Has obvious kidney fibrosis resistance, rich raw material sources and clear chemical structure, can be synthesized, overcomes the problem that the traditional Chinese medicine compound substance is complex and difficult to clarify, and is expected to become an innovative medicine by being developed according with the modern medical law.
The invention aims to research the effect of Chinese Wuning kidney fibrosis through pharmacological experiments, and results show that the Chinese Wuning can obviously reduce the kidney inflammation and the kidney fibrosis degree, has the effect of obviously improving the pathological damage of the kidney, and can be used for preparing health-care products and medicines for preventing and/or treating the kidney fibrosis. The invention relates to an application of Zhongwuning in preparing a medicine for preventing and/or treating renal fibrosis, which is disclosed for the first time.
Disclosure of Invention
The invention aims to solve the technical problem that a medicine for effectively preventing or treating renal fibrosis is lacked in the prior art, and provides application of Zhongwuning in renal fibrosis. The Chinese wuning can well prevent and/or treat kidney fibrosis.
The invention provides application of zhongwuning or pharmaceutically acceptable salt, ester or solvate thereof in preparation of a medicine or a health-care product for preventing and/or treating renal fibrosis, wherein the structural formula of zhongwuning is shown as follows.
In the present invention, the renal fibrosis includes renal interstitial fibrosis and glomerulosclerosis.
Further, the renal fibrosis is renal fibrosis due to nephrectomy.
In the invention, the medicine for preventing and/or treating renal fibrosis is a preparation prepared by taking the wuning or the pharmaceutically acceptable salt, ester or solvate thereof as an active ingredient and adding pharmaceutically common auxiliary materials or auxiliary ingredients.
Wherein the pharmaceutically acceptable salt is an inorganic salt or an organic salt; the inorganic salt is sulfate, nitrate, hydrochloride, hydrobromide or phosphate; the organic salt is acetate, propionate, maleate, oxalate, malate, glycolate, pyruvate, malonate, succinate, citrate, benzoate, fumarate, tartrate, cinnamate, mandelate, methanesulfonate, ethanesulfonate, p-toluenesulfonate or salicylate; the preparation is in a liquid preparation, a solid preparation or a semisolid preparation.
Wherein the daily administration dosage of the Chinese medicine Wuning is 0.0001-80 mg/Kg. Furthermore, the daily administration dosage of the Chinese medicine Wuning is 0.0005-80 mg/Kg. Furthermore, the daily administration dosage of the Chinese medicine Wuning is 0.001-50 mg/Kg.
The kidney fibrosis including renal interstitial fibrosis and glomerular sclerosis is the main pathological basis of the final stage of kidney damage caused by various reasons, the mechanism of renal fibrosis is complex and is related to various factors, wherein the mechanism is mainly related to the proliferation and activation of extracellular matrix cell production cells, imbalance of vasoactive substances, cytokines and extracellular matrix conversion, and the renal interstitial fibrosis is almost a common way for all primary or secondary kidney diseases to progress to the final stage renal failure. It is understood that the factors (such as drugs, diabetes, hypertension, gout, viral/bacterial infection, kidney transplantation, etc.) that can cause chronic inflammation of kidney tissue and fibroblast proliferation are within the scope of the present application.
By "preventing" is meant preventing or reducing the occurrence of renal fibrosis following use in the presence of a potential factor for renal fibrosis. By "preventing" is meant reducing the degree of renal fibrosis, or delaying the progression of myocardial fibrosis, or curing renal fibrosis to normalize it.
As used herein, the term "pharmaceutically acceptable" means having no long term deleterious effects on the general health of the subject being treated.
In the present invention, the term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness of the free base in mexicanin and has no biological or other adverse effects. Pharmaceutically acceptable salts refer to salts formed by converting a base group of a parent compound into a salt, such as inorganic or organic acid salts of a base group (e.g., an amine group), typically prepared by reacting the parent compound with a conventional acid in a solvent system, typically an inorganic acid such as sulfuric, nitric, hydrochloric, hydrobromic, or phosphoric acid; organic acids typically include acetic, propionic, maleic, oxalic, malic, glycolic, pyruvic, malonic, succinic, citric, benzoic, fumaric, tartaric, cinnamic, mandelic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, salicylic, and the like. In the present invention, the term "pharmaceutically acceptable solvate" refers to a combination of wuning and solvent molecules formed by solvation, and may include stoichiometric or non-stoichiometric amounts of solvent, and solvent molecules in the solvent may exist in ordered or non-ordered arrangements.
In the present invention, the term "pharmaceutically acceptable ester" refers to a pharmaceutically acceptable ester of mexicanin, typically under biological conditions in vitro or in vivo, wherein the ester linkage may be cleaved or otherwise reacted from the compound to provide mexicanin. Said ester may be inactive or less active than the meonin itself, such that the meonin does not exert its activity until cleaved from said upper ester. The esterified meonine generally improves the properties of the parent compound (i.e., meonine) in terms of histocompatibility or pharmacokinetics, etc.
In the present invention, the "drug for preventing and/or treating renal fibrosis" may include mexicanin or a pharmaceutically acceptable salt, ester or solvate thereof, and a pharmaceutically acceptable excipient, which may be prepared according to conventional methods in the art, and is generally prepared by mixing mexicanin or a pharmaceutically acceptable salt, ester or solvate thereof, with one or more pharmaceutically conventional excipients (which may be solid excipients or liquid excipients) and/or adjuvants, and making into dosage forms suitable for human or animal use, such as common preparations (such as capsules, tablets, granules or injections, etc.), sustained release preparations, controlled release preparations, targeted preparations, and various microparticle delivery systems. The weight content of the Zhongwuning in the kidney fibrosis medicine can be 5-99%.
The "medicament for preventing and/or treating renal fibrosis" can be administered by any known administration method, and the administration route can be intestinal tract or parenteral tract, such as oral administration, intravenous injection, intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, lung and respiratory tract, skin, vagina, rectum, eye and the like. The dosage form for administration may be a solid dosage form, a semi-solid dosage form, or a liquid dosage form. The liquid dosage forms can be solution (including true solution and colloidal solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including water injection, powder injection and infusion), eye drop, nose drop, lotion, liniment, etc.; the solid dosage form can be tablet (including common tablet, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet, enteric coated tablet, buccal tablet), capsule (including hard capsule, soft capsule, and enteric coated capsule), granule, powder, pellet, dripping pill, aerosol (powder), spray suppository, pellicle, patch, etc.; semisolid dosage forms can be ointments, gels, pastes, and the like.
When the "medicament for preventing and/or treating kidney fibrosis" is a tablet, various excipients which are conventional in the art can be used, including diluents, disintegrants, binders, wetting agents, lubricants and glidants. The diluent can be starch, dextrin, sucrose, glucose, calcium carbonate, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, etc.; the humectant can be water, ethanol, isopropanol, etc.; the disintegrant may be pregelatinized starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, microcrystalline cellulose, sodium bicarbonate and citric acid, polyoxyethylene sorbitol fatty acid ester, sodium dodecyl sulfate, etc.; the binder can be starch slurry, dextrin, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol syrup, Mel, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, and the like. The above tablet can be further made into coated tablet, such as sugar-coated tablet, film-coated tablet, enteric-coated tablet, or double-layer tablet and multi-layer tablet.
When the medicine for preventing and/or treating kidney fibrosis is a capsule, the effective component (Zhongwuning) can be mixed with a diluent and a glidant, and the mixture is directly placed into a hard capsule or a soft capsule. Or mixing the effective components with diluent, binder, and disintegrating agent, making into granule or pellet, and placing into hard capsule or soft capsule. The various diluents, binders, wetting agents, disintegrants and glidants of the above tablets may also be used to prepare the capsules.
When the medicine for preventing and/or treating kidney fibrosis is an injection, the compound of the invention can be prepared into the injection by taking water, ethanol, isopropanol, propylene glycol or a mixture thereof as a solvent and adding a proper amount of solubilizer, cosolvent, pH regulator or osmotic pressure regulator which are commonly used in the field. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-beta-cyclodextrin, etc.; the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. For example, mannitol, glucose, lactose, etc. can be added as proppant for preparing lyophilized powder for injection.
The dosage of the "agent for preventing and/or treating renal fibrosis" to be administered may vary depending on the nature and severity of the disease to be prevented and/or treated, the individual condition of the patient or animal, the route and dosage form of administration, and the like. Generally, the daily clinical dosage of Zhongwuning may range from 0.0001 to 100mg/Kg body weight, preferably from 0.0005 to 80mg/Kg body weight, more preferably from 0.001 to 50mg/Kg body weight. The above-described dosage may be administered in one dosage unit or divided into several dosage units, depending on the clinical experience of the physician and the dosage regimen including the use of other therapeutic means.
The medicine or health-care product for preventing and/or treating the kidney fibrosis can be taken alone or combined with other treatment medicines or symptomatic medicines. When the compounds of the present invention act synergistically with other therapeutic agents, the dosage to be used should be adjusted according to the actual circumstances.
In the application of the invention, the product comprises but is not limited to drugs and health care products. The above preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention without departing from the common general knowledge in the art.
The Wuning in the raw materials used in the invention is synthesized by self (the synthesis process is patented), and the reagents are commercially available.
Drawings
FIG. 1 image of kidney tissue (Masson staining) of rat model group (. times.400).
Figure 2 pictures of uroting high dose group (× 400) kidney tissue (Masson staining) in rats.
Detailed Description
The present invention will be described in further detail with reference to the following examples, but the scope of the present invention is not limited to the specific examples, but is defined by the claims. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
1 experimental materials:
1.1 Experimental animals: SD rats, SPF grade, were supplied by Somogul Biotech, Inc. Producing license numbers: SCXK 2015-030, raised in cages with complete nutrition in an artificial 12h day/night circulating illumination environment at the room temperature of 18-25 ℃ and the relative humidity of 50-60%, the cages are cleaned regularly every day, and rats freely eat and drink water.
1.2 main raw materials and reagents: zhongwuning (provided by Hao doctor pharmaceutical group Co., Ltd., ZWN for short); kits such as Malondialdehyde (MDA) were purchased from Nanjing Biotech.
2 method of experiment
2.1 animal groups: after the SD rats are bred adaptively for 3 days, the SD rats are randomly divided into a blank control group, a sham operation group, a model group, a positive group, a ZWN high dose group, a ZWN low dose group and a ZWN injection group according to the body weight, and 10 rats are selected in each group.
2.2, a molding method: the procedure establishes 5/6 a nephrectomy model. Fasting for 12 hours, weighing, carrying out intraperitoneal injection anesthesia fixation, preparing skin, sterilizing by 20% of urethane (100g/0.5ml), making a longitudinal incision on the skin 1.5cm away from the lower edge of a left rib and the side of the spine under aseptic conditions, separating fascia and intra-abdominal oblique muscle fascia layer by layer, entering a posterior peritoneal cavity, separating a fat layer, exposing a left kidney, carrying out blunt separation on a fat sac, carefully peeling a kidney envelope and adrenal gland, paying attention to avoid damaging the adrenal gland, ligating the left kidney pedicle, cutting off the upper and lower poles 2/3 kidney parenchyma of the left kidney, pressing a wound surface by gelatin sponge to stop bleeding, observing for 30-50 seconds after unfastening a ligature without continuous bleeding, bringing the residual kidney into the abdominal cavity, suturing the muscle layer, the subcutaneous layer and the skin layer by layer, and carrying out local sterilization. After 1 week, the right kidney was removed, and the anesthesia and surgical procedures were the same, i.e., 5/6 nephrectomy model was established. In the sham operation group, only the kidney capsule is separated and no nephrectomy is performed after 2 operations.
2.3 administration mode and time: the high and low dosage components of ZHONGWUNING (ZWN) are administered with ZWN4 mg/kg.d and 2 mg/kg.d medicinal liquid respectively; the injection group of Zhongwuning (ZWN) is injected into the abdominal cavity with 0.1 mg/kg.d liquid medicine; enalapril solution is administered to the positive control group for intragastric administration (10 mg/kg. d), and equal volume of physiological saline is administered to the blank group, the model group and the sham operation group for continuous administration for 30d 1 time a day.
2.4 detection indexes and methods: blood and tissue specimen collection was performed 24h after the last dose: firstly, collecting blood samples, carrying out last administration for 24 hours, anesthetizing a rat by using 20% urethane, placing the rat on a sterile operating table, opening the abdominal cavity, exposing the abdominal aorta, carrying out abdominal aorta blood collection at 3000rpm/min by using a sterile blood collector and a No. 7 needle, and centrifuging for 10min to separate serum. Freezing at-80 deg.C for use. Collecting and blood sampling tissue specimens, dissecting animals, separating kidneys on two sides, fully fixing 10% neutral formaldehyde, and observing pathological changes of rat kidneys by adopting HE staining and Masson staining. All detection indexes are detected according to the kit instructions.
2.5 statistical methods: metering data adoption
The data obtained from each group are compared with the model control group, normal distribution is met, SPSS 21.0 single-factor variance analysis is adopted, and non-parameter check rank sum analysis is adopted for the non-conforming persons.
3 results of the experiment
(1) Effect of ZWN on weight Change in rats
The body weight of each group of rats showed a tendency to increase overall during the administration period. After continuous administration for 30 days, the weight of rats in the model group is obviously lower than that in the sham operation group, and compared with the model group, the weight average of each administration group of ZWN is increased, wherein the weight of rats in the ZWN high and low dose groups and the ZWN injection group is obviously increased, and the whole state of animals is better. The results are shown in Table 1.
TABLE 1 Effect of mean body weight change in rats of various groups
| Group of | Body weight (g) on day 1 before surgery | Body weight (g) on day 30 of dosing |
| Blank group | 191.50±23.91 | 348.95±28.22 |
| Artificial operation group | 184.15±20.02 | 326.47±24.15 |
| Model set | 187.60±19.13 | 292.81±30.43 |
| Positive group | 185.46±22.14 | 339.50±20.25* |
| ZWN high dose group | 186.45±21.98 | 357.34±27.78** |
| ZWN Low dose group | 188.35±20.41 | 323.51±32.63 |
| ZWN injection group | 186.87±20.82 | 348.22±24.18* |
Note: comparison with blank group△P＜0.05，△△P is less than 0.01; comparison with model group*P＜0.05，**P＜0.01
(2) Effect of ZWN on rat Kidney histopathology
HE results show that ZWN administration groups have the effect of remarkably reducing renal tubular injury, renal interstitial inflammation and fibrosis. Scoring the kidney HE results of each group according to the scoring standard of the table 2, compared with the blank group, the difference of the sham operation group is not significant (P is more than 0.05), the kidney damage pathological grading score of the model group is significantly increased, and the statistical significance is achieved (P is less than 0.01); compared with the model group, the total renal components of the positive group, the ZWN high dose group, the ZWN low dose group and the ZWN injection group are all remarkably reduced, wherein the kidney injury protection of the ZWN high dose group is most remarkable (P < 0.05). The scoring results are shown in table 3.
TABLE 2 grading of renal toxicity Damage pathology
TABLE 3 statistical results of rat renal tissue injury scores
| Grouping | Kidney injury score |
| Blank group | 0.00±0.00 |
| Artificial operation group | 0.00±0.00 |
| Model set | 3.96±1.15** |
| Positive group | 2.81±1.60△ |
| ZWN Low dose group | 3.04±2.04△ |
| ZWN high dose group | 2.56±1.07△△ |
| ZWN injection group | 2.77±1.52△ |
Note: compared with the blank group, the sham operation group and the model group respectively have 0.01 < P <0.05 and 0.01;
compared with the model group, the dosage group is 0.01 <△P<0.05，△△P<0.01。
(3) Effect of ZWN on rat Kidney tissue fibrosis
Masson staining result analysis shows that compared with a blank group, the kidney fibrosis rate of a false operation group is similar, the kidney fibrosis rate of a model group is obviously increased, and the kidney fibrosis rate has significant difference (P is less than 0.05); compared with the model group, the fibrosis rate of the high-dose group is obviously reduced, and the high-dose group has significance (P is less than 0.05), which prompts that the anti-renal fibrosis effect of the ZWN high-dose group and the ZWN injection group is significant; the fibrosis rate of ZWN low dose group and positive group was reduced but the difference was not significant (P > 0.05), and the results are shown in Table 4 and FIG. 1 and FIG. 2.
TABLE 4 statistical results of Masson staining score for ZWN on rat renal tissue injury
Note: model group and sham group were compared to blank group,. P <0.05,. P <0.01, respectively;
compared with the model group, the medicine group is used,△P<0.05，△△P<0.01。
(4) effect of ZWN on serum MDA
The serum MDA detection result shows that compared with a blank group, the serum MDA value of a rat in a pseudo-operation group is increased (P is less than 0.05), the serum MDA value of a rat in a model group is increased more significantly (P is less than 0.01), and the fact that the lipid peroxidation reaction is enhanced due to operation and 5/6 kidney excision is suggested. Compared with the model group, ZWN medicinal groups and positive medicinal groups have a reducing effect on the serum MDA level of the model rat, ZWN high-dose groups and ZWN injection groups have a remarkable effect on reducing the serum MDA level, and research results suggest that ZWN has a certain relation with the improvement effect on the kidney function and the antioxidant stress. The results are shown in Table 5.
TABLE 5 Effect of ZWN on model rat serum MDA
| Group of | MDA(nmol/L) |
| Blank group | 3.35±3.26** |
| Artificial operation group | 7.41±6.29** |
| Model set | 14.66±6.50 |
| Positive group | 9.53±2.83△ |
| ZWN high dose group | 9.15±3.46△ |
| ZWN Low dose group | 11.66±4.41 |
| ZWN injection group | 9.68±2.91△ |
Note: p <0.05, P <0.01 compared to blank; comparison with model group△P＜0.05，△△P＜0.01；
Based on the above results, ZWN has significant effects of resisting nephritis and renal fibrosis, and can protect kidney tissue injury.
Claims (9)
1. The application of the Chinese medicine Wuning or the pharmaceutically acceptable salt, ester or solvate thereof in preparing the medicine or the health care product for preventing and/or treating the kidney diseases, wherein the kidney diseases are kidney fibrosis or nephritis, and the structural formula of the Chinese medicine Wuning is shown as the following.
2. The use of claim 1, wherein the renal fibrosis is that resulting from chronic inflammation of renal tissue or fibroblast proliferation caused by a variety of factors.
3. The use of claim 2, wherein the various factors are drugs, diabetes, hypertension, gout, viruses, bacterial infections, or kidney transplants.
4. The use of claim 1, wherein the renal fibrosis is renal interstitial fibrosis.
5. The use of claim 1, wherein the renal fibrosis is renal fibrosis due to nephrectomy.
6. The use of claim 1, wherein the nephritis is renal interstitial inflammation.
7. The use of claim 1, wherein the medicament for preventing and/or treating renal fibrosis is a preparation prepared from wuning or a pharmaceutically acceptable salt, ester or solvate thereof as an active ingredient, together with pharmaceutically acceptable adjuvants or auxiliary ingredients.
8. The use of claim 7, wherein the pharmaceutically acceptable salt is an inorganic salt or an organic salt.
9. The use of claim 7, wherein the formulation is in the form of a liquid, solid or semi-solid formulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018106925324 | 2018-06-28 | ||
| CN201810692532 | 2018-06-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110652510A true CN110652510A (en) | 2020-01-07 |
| CN110652510B CN110652510B (en) | 2022-02-15 |
Family
ID=69028754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910582562.4A Active CN110652510B (en) | 2018-06-28 | 2019-06-28 | Application of Zhongwuning in preparing medicine for preventing and treating renal fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110652510B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270634A (en) * | 2023-03-31 | 2023-06-23 | 好医生药业集团有限公司 | Application of Zhongwuning in preparing medicine for preventing and treating liver diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107913273A (en) * | 2016-10-09 | 2018-04-17 | 胡卓伟 | The application of mesaconine |
-
2019
- 2019-06-28 CN CN201910582562.4A patent/CN110652510B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107913273A (en) * | 2016-10-09 | 2018-04-17 | 胡卓伟 | The application of mesaconine |
Non-Patent Citations (1)
| Title |
|---|
| 李莎莎: "《中国优秀博硕士学位论文全文数据库（博士）医药卫生科技辑》", 15 January 2015 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270634A (en) * | 2023-03-31 | 2023-06-23 | 好医生药业集团有限公司 | Application of Zhongwuning in preparing medicine for preventing and treating liver diseases |
| CN116270634B (en) * | 2023-03-31 | 2024-04-09 | 好医生药业集团有限公司 | Application of Zhongwuning in preparing medicine for preventing and treating liver diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110652510B (en) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11135199B2 (en) | Sublingual pharmaceutical compositions of edaravone and (+)-2-borneol | |
| US10314806B2 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| US20220331281A1 (en) | Pharmaceutical composition and application thereof | |
| US20220143074A1 (en) | Chondroitin sulfate polysaccharide, and semi-synthetic preparation method therefor and use thereof | |
| RU2388466C2 (en) | Phenoxyalkyl carbonic acids derivative in treatment of inflammatory diseases | |
| CN110652510B (en) | Application of Zhongwuning in preparing medicine for preventing and treating renal fibrosis | |
| CN103012345B (en) | Luteolin alpha crystal form substance, preparation method thereof as well as pharmaceutical composition and application thereof | |
| WO2020143744A1 (en) | New formulations containing leukotriene receptor antagonists | |
| AU2018446089B2 (en) | Pharmaceutical use of anemoside B4 against acute gouty arthritis | |
| CN110652511B (en) | Application of Zhongwuning in preparation of medicine for preventing and treating renal failure | |
| CN111184706B (en) | Active medicine for preventing and treating cholecystitis and application thereof | |
| CN114984056B (en) | Natural product extract for treating Crohn's disease and application thereof | |
| CN114159435B (en) | Application of Fuziling in preparing medicine for treating arthritis | |
| CN114306292A (en) | Application of gnelitol in preparing medicine for treating osteoporosis bone defect | |
| CN1923205B (en) | Application of (-)doxazosin in preparing medicine for treating lower urinary tract symptom and bladder excessive activities diseases | |
| CN117257803B (en) | Application of lurasidone in preparation of drugs for treating or preventing ischemia/reperfusion injury and cytoprotective drugs | |
| CN115671104B (en) | Application of compound in preparation of medicine for preventing or treating ischemic cerebral apoplexy | |
| CN112915193B (en) | Application of KP-1 in preparation of medicine for treating chronic lung diseases | |
| CN114569615B (en) | Use of methotrexate analogues for the treatment of inflammatory skin diseases | |
| CN118512441A (en) | Application of CBL0137 in preparation of medicament for inhibiting airway smooth muscle hyperplasia of asthma | |
| CN112358477A (en) | Medicine for treating cholecystitis and preparation method thereof | |
| US20120225817A1 (en) | Therapeutic agent for gastrointestinal disease | |
| CN117562912A (en) | Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery | |
| CN118512430A (en) | Application of midodrine hydrochloride in medicines for relieving intestinal ischemia reperfusion injury | |
| CN118236359A (en) | Application of terbutaline sulfate in preventing and treating intestinal ischemia reperfusion injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |